Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Hammer

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Australian and New Zealand Journal of Medicine|May 9, 2000
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East AsiaP Phanuphak, M L Grayson, S Sirivichayakul, et al.
Journal of Virology|May 1, 1997
Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vectorR T Inouye, B Du, D Boldt-Houle, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 30, 2010
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American womenE M Stein, M T Yin, D J McMahon, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1994
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study GroupD L Mayers, A J Japour, J M Arduino, et al.
The New England Journal of Medicine|October 10, 1996
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study TeamD A Katzenstein, S M Hammer, M D Hughes, et al.
Journal of Clinical Microbiology|September 1, 1996
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials GroupW A Scott, D Brambilla, E Siwak, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Australian and New Zealand Journal of Medicine|May 9, 2000
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East AsiaP Phanuphak, M L Grayson, S Sirivichayakul, et al.
Journal of Virology|May 1, 1997
Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vectorR T Inouye, B Du, D Boldt-Houle, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 30, 2010
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American womenE M Stein, M T Yin, D J McMahon, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1994
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study GroupD L Mayers, A J Japour, J M Arduino, et al.
The New England Journal of Medicine|October 10, 1996
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study TeamD A Katzenstein, S M Hammer, M D Hughes, et al.
Journal of Clinical Microbiology|September 1, 1996
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials GroupW A Scott, D Brambilla, E Siwak, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
The New England Journal of Medicine|October 10, 1996
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study TeamS M Hammer, D A Katzenstein, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 TeamS A Fiscus, M D Hughes, J L Lathey, et al.
Pageof 10